US FDA flags shortage of Becton Dickinson's blood test tubes
July 10 (Reuters) -The U.S. Food and Drug Administration issued an alert on Wednesday to laboratories and healthcare providers of a shortage of Becton Dickinson' BDX.N blood test tubes used in diagnosing bacterial and fungal infections.
The regulator urged providers to prioritize patients at the highest risk such as those displaying signs of bloodstream infections, which can often be deadly.
WHY IT'S IMPORTANT
The disruption in supply of this device is expected to impact patient diagnosis, follow-up treatment, and antimicrobial management efforts, according to the FDA.
Becton's BACTEC blood culture media help detect bacterial and fungal infections in the bloodstream. Early detection of an infection help prevent worsening of a condition called sepsis, which occurs when the immune system has a dangerous reaction to an infection.
CONTEXT
Last month, Becton issued a letter warning of potential delays in its BACTEC blood culture media supply over the coming months due to reduced availability of plastic bottles from a supplier.
The company said it will provide an update on supply by September.
KEY QUOTES
"While this supplier issue is not expected to have a material financial impact on BD, we are fully focused on returning the supply of blood culture vials to normal levels," Nikos Pavlidis, president of BD Diagnostic Solutions, said in a statement.
Becton said it is taking measures to address the issue, including the use of air shipments and modifying manufacturing schedules for rapid production.
BY THE NUMBERS
At least 1.7 million adults in the U.S. develop sepsis each year, and nearly 270,000 die as a result of it, according to the Centers for Disease Control and Prevention.
Reporting by Mariam Sunny in Bengaluru; Editing by Alan Barona
Related Assets
Latest News
Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.
All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.
Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.
